TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of GDX012 in Patients With MRD Positive AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years old~* Weight ≥ 40 kg~* Anticipated life expectancy \> 3 months prior to lymphodepletion~* Karnofsky Performance Score ≥ 70%~* Histologically confirmed diagnosis of AML~* In complete response (CR) (including CRi/CRp); patients in first, second or subsequent CR (including CRi/CRp) are permitted~* MRD detected in bone marrow by MFC~* Negative pregnancy test (females of childbearing potential only)~* Agree to use effective birth control~* Left ventricular ejection fraction (LVEF) ≥ 50%~* Platelet Count ≥ 20 x 109/L~* Prothrombin Time or INR ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)~* Partial Thromboplastin Time ≤ 1.5 x ULN (unless receiving therapeutic anticoagulation)~* Hemoglobin ≥ 8.0 g/dL~* Creatinine Clearance ≥ 40mL/min~* Serum Total Bilirubin ≤ 1.5 x ULN (unless documented Gilbert's Syndrome with Direct Bilirubin \< 35% of Total Bilirubin)~* ALT ≤ 2.5 x ULN~Exclusion Criteria:~* Cytotoxic chemotherapy within 3 weeks~* Immune therapy within 4 weeks~* Immunosuppressive therapy within 2 weeks (with exceptions)~* Investigational treatment or interventional clinical trial within 4 weeks or 5 half-lives (if known), whichever is longer~* Major surgery within 4 weeks and/or not fully recovered from surgery-related toxicities~* Known hypersensitivity to chemotherapy, other agents, or excipients used in this study~* Female patient that is pregnant or lactating/breastfeeding~* Ongoing toxicity from prior anti-cancer therapy that have not recovered to ≤ Grade 1 (with exceptions)~* History of chronic or recurrent autoimmune or immune-mediated disease requiring steroids or other immunosuppressive treatments (including anti-tumor necrosis factor agents)~* Active CNS involvement (i.e. leukemic infiltration)~* Any other malignancy that requires active therapy~* Uncontrolled intercurrent illness (i.e. acute coronary syndrome in the last 6 months)~* Active infection with HIV, Hepatitis B or Hepatitis C~NOTE: other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GDX012 Suspension for IV Infusion (Type: EXPERIMENTAL): Allogeneic cell therapy that is enriched for Vδ1+ γδ T cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion criteria~1. Histologically confirmed differentiated or poorly differentiated thyroid cancer that is metastatic or unresectable~2. Patients refractory to radio iodine~3. Radiologic evidence of clinically relevant disease progression (as per RECIST 1.1)~4. Measurable disease (by RECIST Version 1.1 criteria)~5. ECOG performance status of ≤ 1~6. Adequate hematologic, renal and liver function~7. Negative serum pregnancy test in premenopausal women.~8. Signed informed consent~Main Non-Inclusion criteria~1. Other histological subtypes of thyroid tumors: anaplastic, medullary, lymphoma or sarcoma~2. Active CNS metastases~3. Prior chemotherapy. Patients treated previously with molecular targeted therapies could be included.~4. Severe, acute or chronic medical or psychiatric condition or laboratory abnormality which in the judgment of the investigator would make the patient inappropriate for entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine -oxaliplatine combination (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Effectiveness of the DuraHeart™ LVAS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~1. Approved for cardiac transplantation~2. Listed with UNOS on the Status 1 list~3. Patient for whom LVAS implantation is planned as a clinically indicated bridge to cardiac transplantation~Exclusion Criteria:~The following are general criteria; more specific conditions are included in the study protocol:~1. Contraindication to the administration of warfarin or anti-platelet agents~2. Primary coagulopathy or platelet disorder~3. Acute myocardial infarction within 48 hours prior to enrollment~4. Anticipated need for RVAD support or ECMO at the time of LVAS implantation~5. Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty, passive restraint device (i.e., CorCapTM Cardiac Support Device) or surgically implanted left ventricular assist device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Historical Data (Type: OTHER): DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Liver transplantation candidates with age ≥ 18 years, no clinical or radiological evidence of active tuberculosis and negative pregnancy test (if applicable)who must meet one or more of the following criteria:~* PPD skin test (initial or after a booster effect) \>5 mm. Alternatively, the determination may be made by the interferon gamma (IFN-g) production in PPD-stimulated lymphocytes using the Quantiferon-TB or ELISPOT assays.~* Past history of tuberculosis not properly treated.~* Past history of contact with a patient with active TB.~* Chest x-ray consistent with past untreated TB (apical fibronodular lesions, calcified solitary nodule, calcified lymph nodes or pleural thickening).~The patient must give their written informed consent.~Exclusion Criteria:~* Lack of consent to participate in the study.~* Intolerance or allergy to levofloxacin or to isoniazid.~* Documented contact with tuberculosis resistant to levofloxacin or to isoniazid.~* Treatment in the previous month with drugs with potential activity against Mycobacterium tuberculosis, (especially quinolones).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- levofloxacin (Type: EXPERIMENTAL): Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
- Isoniazid (Type: ACTIVE_COMPARATOR): Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 45 years old~* with a painful symptomatic endometriosis~* with symptoms evolve for more than 6 months~* diagnosis based on clinical and radiological criteria : pain in the examination and/or palpation of endometriosis lesion(s) and lesion(s) objectified by MRI performed and interpreted by a radiologist referent dating less than three months at the time of inclusion~* no history presenting therapeutic surgery for endometriosis~* Accepting medical management~* without hormonal treatment (oestroprogestative, progestative or Luteinizing Hormone-Releasing Hormone (LHRH) analog) since at least 15 days~* No family history of deep venous thromboembolic disorders~* No abnormalities of hemostasis known~* Not pregnant at inclusion visit~Exclusion Criteria:~* Patient with a strict indication for surgery (ureteral disease with renal impact, digestive disease with occlusion, infertility with desire for immediate pregnancy, ovarian cyst ≥ 4cm)~* reproductive upper tract infections~* with one or more varicose veins~* with one or more breast abnormalities (ACR 3 or more)~* with contraindication for one of two treatments~* with contraindication for RMI~* taking drug treatment that could alter the concentration of the study treatments

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Implant (Type: EXPERIMENTAL): Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
- Oral treatment (Type: ACTIVE_COMPARATOR): Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with newly diagnosed AML based on the World Health Organization classification who have persistent disease after their first course treatment with an anthracycline and cytarabine~2. Able to understand and have the ability to provide written informed consent~3. Patients over 18 years of age~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~5. Left ventricular ejection fraction (LVEF) ≥ 50%~6. Negative urine pregnancy test for all females~7. All subjects must agree to use an effective method of contraception while receiving the study drugs~Exclusion Criteria:~1. Diagnosis of acute promyelocytic leukemia~2. Relapsed AML~3. Prior use of clofarabine~4. Previous allogeneic or autologous hematopoietic cell transplantation~5. Impaired liver function (serum total bilirubin \> 2.0 mg/dL, alanine aminotransferase and aspartate aminotransferase ≥ 4 x the upper limit of normal)~6. Impaired renal function (serum creatinine ≥ 2.0 mg/dL)~7. Uncontrolled or life-threatening infection that is not responding to antimicrobial therapy~8. History of a psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent~9. Concurrent active malignancy; exceptions include patients who have been disease free for 5 years, patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, or patients with another malignancy that is indolent or definitively treated~10. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory or cardiac disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clofarabine and Cytarabine (Type: EXPERIMENTAL): Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced non-squamous NSCLC~* No prior chemotherapy for advanced disease~* ECOG performance status 0 or 1~* Measurable disease~* Life expectancy \> 3 months~* Normal bone marrow, renal and hepatic function~* Ability to take oral medications~* Willingness to sign informed consent~Exclusion Criteria:~* History of brain metastasis~* Evidence of thromboembolic phenomenon and treatment with anticoagulants~* Pregnancy~* Uncontrolled inter-current illness~* Prior therapy with Paclitaxel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Phase I dose escalating scheme
- 2 (Type: EXPERIMENTAL): Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of Digital Chest-X-ray (CXR) to Assess Lung Recruitment in ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* intubation and mechanical ventilation in the ICU~* Ramsay score 6 under sedation and analgesia~* ICU respirator implemented with pressure-volume curve device~* age equal to or greater than 18 years~* ARDS defined from the Berlin criteria~* absence of pneumothorax on the CXR before the study~* Absence of pleural effusion greater than 500 ml estimated from ultrasonography.~* no child-bearing woman~* written inform consent signed by the next of kin~Exclusion Criteria:~* Pneumothorax~* Pleural effusion greater than 500 ml estimated from ultrasonography~* Thoracic surgery in the last 3 months~* Contra-indication to CXR~* contra-indication to PEEP of 15 cm H2O~* contra-indication to PEEP of 15 or PEEP 15 mandated~* pressure-volume curve not feasible~* refusal to participate~* language barrier of the next of kin~* child-bearing woman~* person under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEEP 5 (Type: OTHER): level of PEEP of 5 cm H2O randomly applied to the patient
- PEEP 15 (Type: OTHER): level of PEEP of 15 cm H2O randomly applied to the patient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Probable or confirmed infection by SARS-CoV2~* Intubated and mechanically ventilated~* Moderate/severe ARDS defined by the Berlin criteria (PaO2/FiO2 ≤200mmHg with PEEP ≥5cmH20)~* Onset of moderate/severe ARDS in less than 48 hours before randomization~Exclusion Criteria:~* Pregnancy or active lactation~* Known history of dexamethasone allergy~* Daily use of corticosteroids in the past 15 days~* Clinical indication for corticosteroids use for other diseases (i.e refractory septic shock)~* Patients who did use corticosteroids during hospital stay for periods equal or greater than two days~* Use of immunosuppressive drugs~* Cytotoxic chemotherapy in the past 21 days~* Neutropenia due to hematological or solid malignancies with bone marrow invasion~* Patient expected to die in the next 24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Dexamethasone. After randomization, dexamethasone \[20mg IV 1x/day for 5 days, followed by 10mg IV 1xd for 5 days\] + standard treatment (according to the treatment protocol for 2019-nCoV infection).
- Control (Type: NO_INTERVENTION): Standard treatment (according to the treatment protocol for 2019-nCoV infection).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Work Related Rehabilitation in Patients With Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with non-specific low back pain sick listed from 6-8 weeks and who are permanently employed.~Exclusion Criteria:~* Patients with infection, tumors, osteoporosis, fracture, structural deformity, inflammatory disorder, radicular syndrome or cauda equina syndrome, spinal stenosis or spondylolysis/ listesis, serious somatic disease and/or psychic disease and patients with a poor proficiency in Norwegian.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: ACTIVE_COMPARATOR): The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cannabidiol - an in Vivo Innovative Drug Delivery Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent given by the subject~* Negative drug screening at the time of screening~* Non-smoking~* In female participants in fertile age, reliable contraception, which means contraception's Pearl index is equal to or smaller than 1.~* Body Mass Index between 18.5 kg/m2 and 30 kg/m2~Exclusion Criteria:~* Lack of accountability~* Pregnancy or lactation phase in females at the time of screening~* Any known psychiatric or neurological illness in the participant's history.~* Known family history regarding psychiatric disorders with an increased lifetime risk for psychiatric disorders in the participant (investigators qualified judgement)~* Relevant use of cannabis (which is defined on the present state of knowledge as more than five times lifetime consumption and/or more than two consumptions during the last year)~* Consumption of any illicit drugs (except cannabis in history, see above)~* Severe physical (internal) or neurological illness, especially cardiovascular, renal, advanced respiratory, haematologic or endocrinologic disorders or infectious diseases (acute hepatitis A, B or C or HIV) assessed at the time of the screening by the subject's history, clinical examination and laboratory testing, as assessed by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Reference formulation (Type: ACTIVE_COMPARATOR): Cannabidiol capsule, 200 mg
- New formulation (Type: EXPERIMENTAL): Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: OxyPrem Validation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Substudy 1 (healthy adult volunteers)~Inclusion Criteria:~* Healthy adult~* Signed informed consent~Exclusion Criteria:~* Dense black hair at the location of measurement~* Neurological diseases.~Substudy 2 (preterm infants)~Inclusion Criteria:~* Pre-term neonates (gestational age at birth less than 37 weeks)~* Signed informed consent by at least one parent~Exclusion Criteria:~* Clinically instability~* Malformations

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- precision and accuracy study (Type: EXPERIMENTAL): precision and accuracy of Oxyprem are studied

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility